Physician profile
Jane J Lee
NPI 1396888194
$8,611.00
in general payments reported to CMS, 2019-2025
37 companies · $2,611 in 2025
The $2,611 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $847 · 2020: $192 · 2021: $687 · 2022: $1,519 · 2023: $1,255 · 2024: $1,500 · 2025: $2,611.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,275 · Education: $91.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,274.75 |
| Education | $91.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,419.19 | 2019-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $985.99 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $890.55 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Genzyme Corporation | $743.75 | 2019-2025 | |
| Intuitive Surgical, INC. | $591.66 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $550.99 | 2021-2024 | Takhzyro, Cuvitru, Hyqvia |
| Csl Behring | $431.20 | 2019-2025 | Haegarda, Hizentra, Andembry |
| Pfizer INC. | $309.42 | 2019-2025 | |
| Kaleo, INC. | $198.86 | 2019-2023 | Auvi-Q |
| Alk-Abello, INC | $190.59 | 2019-2025 | Neffy, Ragwitek, Grastek |
| Novartis Pharmaceuticals Corporation | $187.13 | 2022-2025 | |
| Organon LLC | $159.05 | 2025 | Vtama |
| Biocryst US Sales Co., LLC | $153.06 | 2021-2025 | Orladeyo |
| Pharming Healthcare, INC. | $152.57 | 2023-2025 | Ruconest |
| Octapharma USA, INC. | $150.21 | 2022-2024 | Cutaquig |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $144.71 | 2024 | Ayvakit |
| Sanofi-Aventis U.S. LLC | $139.26 | 2019-2022 | |
| Jubilant Hollisterstier LLC | $126.59 | 2025 | |
| Optinose US, INC. | $121.13 | 2019-2021 | |
| Amgen INC. | $114.23 | 2022-2025 | Tezspire |
| Grifols USA, LLC | $91.65 | 2025 | Gamunex-C |
| Incyte Corporation | $87.30 | 2022-2025 | Opzelura |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.57 | 2019-2020 | |
| Genentech USA, INC. | $73.10 | 2021-2024 | Xolair |
| Ars Pharmaceuticals Operations, INC. | $71.05 | 2025 | Neffy |
| Hospira, INC. | $68.91 | 2024-2025 | |
| Recordati_rare_diseases_inc. | $67.93 | 2025 | Isturisa |
| Galderma Laboratories, L.P. | $47.97 | 2025 | Nemluvio |
| Hikma Pharmaceuticals USA | $39.02 | 2023-2024 | Ryaltris |
| Aimmune Therapeutics, INC. | $37.28 | 2021-2023 | |
| Leo Pharma INC. | $35.77 | 2022 | |
| Ionis Pharmaceuticals, INC. | $35.57 | 2025 | Dawnzera |
| Teva Pharmaceuticals USA, INC. | $35.12 | 2019-2021 | |
| Ethicon US, LLC | $26.89 | 2022 | |
| Abbvie INC. | $21.48 | 2023 | |
| Merck Sharp & Dohme LLC | $15.01 | 2021 | |
| Eyevance Pharmaceuticals LLC | $12.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.